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Introduction {#path5374-sec-0001}
============

With humans now having a longer lifespan, neurodegenerative disorders, cardiovascular diseases, and cancer become the most devastating illnesses currently affecting human populations. Alzheimer\'s disease (AD), a neurodegenerative disease and the most prevalent form of senile dementia, is associated with a deterioration in memory and a loss of cognitive function; it usually causes death in 3 to 9 years after diagnosis [1](#path5374-bib-0001){ref-type="ref"}. AD is characterized by the presence of amyloid plaques, which mainly consist of amyloid β (Aβ) peptides, as well as the presence of neurofibrillary tangles that contain hyperphosphorylated tau protein. These features result in progressive neuronal cell death, a loss of synapses within the brain, memory impairment, and cognitive disturbances [2](#path5374-bib-0002){ref-type="ref"}, [3](#path5374-bib-0003){ref-type="ref"}. Loss of neurons in the entorhinal cortex, hippocampus, frontal cortex, parietal cortex, and temporal cortex of patients with AD has been documented [4](#path5374-bib-0004){ref-type="ref"}. Previous reports have proposed various pathological mechanisms for AD, as well as various potential therapeutic targets that have been suggested for evaluation in clinical trials. However, the cause(s) of AD are not fully understood and there are no supplements or medications that have been shown to decrease the risk of AD.

Neurons as cells are highly energy‐dependent and rely on mitochondria to supply ATP for their many energy‐demanding neuronal functions, such as synaptic transmission, vesicle release, ion receptors, channel‐related signaling, and re‐uptake/recycling of neurotransmitters [5](#path5374-bib-0005){ref-type="ref"}. Therefore, any defect that affects mitochondria‐related functions is likely to lead to neuronal death. Previous studies have revealed that oxidative stress occurs before Aβ plaque formation, which suggests that mitochondrial dysfunction and the accumulation of reactive oxygen species (ROS) play a pivotal role in AD pathogenesis [6](#path5374-bib-0006){ref-type="ref"}, [7](#path5374-bib-0007){ref-type="ref"}. Accumulation of Aβ in mitochondria leads to abnormal mitochondrial structure and increases the amounts of mitochondrial DNA, both of which are known to be compensatory responses to mitochondrial oxidative damage [8](#path5374-bib-0008){ref-type="ref"}. Furthermore, Aβ has multiple adverse effects on the functioning and integrity of both presynaptic and postsynaptic terminals, including the induction of oxidative stress, impairment of calcium homeostasis, and perturbation of the functioning of the mitochondria and the endoplasmic reticulum (ER). These features mirror the primary alterations in synaptic/axonal functionality and the structural abnormalities present in patients with AD [9](#path5374-bib-0009){ref-type="ref"}. Damage to the mitochondria often blocks the antioxidant mechanisms used to remove ROS and prevent oxidative stress [10](#path5374-bib-0010){ref-type="ref"}; as a consequence, it is thought that the increase in oxidative stress induces tau phosphorylation and Aβ upregulation [11](#path5374-bib-0011){ref-type="ref"}. Therefore, therapeutic agents that help to maintain mitochondrial integrity and functioning, as well as ones that help to eliminate Aβ‐induced ROS, should have neuroprotective properties against Aβ toxicity in the brains of patients with AD.

The major factor associated with the development of neurodegenerative diseases is aging. Our studies have revealed that CDGSH iron--sulfur domain‐containing protein 2 (Cisd2) plays a vital role in controlling mammalian lifespan [12](#path5374-bib-0012){ref-type="ref"}, [13](#path5374-bib-0013){ref-type="ref"}. The first molecular analysis of Cisd2 indicated that Cisd2 is one of the markers associated with early neuronal differentiation [14](#path5374-bib-0014){ref-type="ref"}. Using Cisd2 knockout mice, we have demonstrated previously that Cisd2 deficiency shortened the lifespan of mice and this was accompanied by an accelerated aging phenotype. In addition, neuron and muscle degeneration were the primary defects observed using this mouse model [12](#path5374-bib-0012){ref-type="ref"}. Conversely, a persistent expression of Cisd2 in mice extended their lifespan and prevents age‐dependent neuron and muscle degeneration. Furthermore, overexpression of Cisd2 appeared to protect mitochondria against age‐associated structural alterations and the functional decline associated with old age [13](#path5374-bib-0013){ref-type="ref"}. Accordingly, it was of great interest to investigate with use of a mouse model whether an increase in Cisd2 expression was able to protect against the toxicity of Aβ and reduce the development of hippocampal neuronal damage, thereby attenuating AD pathogenesis by maintaining mitochondrial integrity and synaptic structure.

Materials and methods {#path5374-sec-0002}
=====================

Mouse models {#path5374-sec-0003}
------------

The AD mouse model (JAX004462, kindly provided by Dr. Ding‐I Yang of National Yang Ming University) expresses a mutant chimeric mouse/human amyloid precursor protein (Mo/HuAPP695swe) and a mutant human presenilin 1 (PS1‐dE9), predominantly in the neurons of central nervous system (CNS); both transgenes are controlled by a mouse prion protein (MoPrP) promoter and are co‐integrated at the same chromosome location and thus co‐segregate [15](#path5374-bib-0015){ref-type="ref"}. The AD mice were crossed with Cisd2 BAC transgenic mice to obtain AD mice carrying Cisd2 transgenes (AD;Cisd2TG). We used C57BL/6 as the genetic background for all mouse lines used as models. In addition, AD mice were also bred with Cisd2 knockout mice (KO) to generate AD mice with a Cisd2 deletion (AD;Cisd2KO). The genotypes of the mice were determined by PCR using tail genomic DNA. The mice were bred in a specific pathogen‐free facility. The animal protocol was approved by the Institutional Animal Care and Use Committee of the National Yang‐Ming University.

Cisd2 BAC transgenic mice {#path5374-sec-0004}
-------------------------

Cisd2 BAC transgenic mice, mouse Cisd2 genomic DNA obtained from a BAC clone (201 J1) was generated and reported previously [16](#path5374-bib-0016){ref-type="ref"}. The Cisd2 BAC transgene was detected by Southern blot analysis using a probe designed on chloramphenicol resistance gene (Cm^R^), specifically a 5.65 kb NcoI fragment. The expression levels of Cisd2 protein in line A301 and A302 were about two‐ to three‐fold higher than wild‐type (WT) mice.

Brain tissue sampling {#path5374-sec-0005}
---------------------

Mice were anesthetized with an intraperitoneal injection of 2,2,2‐tribromoethanol in phosphate‐buffered saline (PBS) and perfused with ice‐cold 0.9% saline. Brains were then removed and divided in a sagittal manner. The left hemibrain was post‐fixed in phosphate‐buffered 4% paraformaldehyde and transferred to 30% sucrose to dehydrate the sample\'s cells. This hemisphere was used to produce frozen blocks using optimum cutting temperature (OCT) compound, whereas the right hemibrain was frozen and stored in liquid nitrogen for DNA, RNA, and protein extraction. To perform diffusion MRI analysis, mice were anesthetized and perfused, and then brains were removed and fixed in formalin (buffered, 10%). After MRI analysis, the whole brain was dehydrated and embedded in paraffin.

Full details of materials and methods for western blotting, transmission electron microscopy, immunofluorescence staining, thioflavin‐S amyloid labeling, Nissl staining (Cresyl violet staining), image analysis, oxygen consumption rate (OCR) measurement, diffusion MRI analysis, hippocampal RNA isolation, library preparation and RNA sequencing, and analysis of RNA sequencing are provided in supplementary material, Supplementary materials, and methods.

Statistics {#path5374-sec-0006}
----------

Results are presented as means ± SD. Comparisons between two groups were carried out using Student\'s *t*‐test. Mouse survival rates were calculated using the Kaplan--Meier method, and the differences in the survival of the different groups of mice were determined using the log‐rank (Mantel--Cox) test. When analyzing statistical differences between different groups of mice, *p* \< 0.05 was considered significant.

Results {#path5374-sec-0007}
=======

Cisd2 upregulation in AD mice promotes their survival and protects against neuronal loss {#path5374-sec-0008}
----------------------------------------------------------------------------------------

To investigate whether Cisd2 overexpression can ameliorate the phenotypes associated with AD, we used a mouse AD model, namely APPswe and PS1‐dE9 double transgenic (APP/PS1) mice. This model shows accelerated plaque formation and logarithmic plaque deposition. This AD model is most useful when investigating the biochemical aspects of APP metabolism and the presence of intracellular damage compared to other AD models, which are most helpful when studying behavioral phenotypes [17](#path5374-bib-0017){ref-type="ref"}, [18](#path5374-bib-0018){ref-type="ref"}. We crossed the AD mice with our Cisd2 BAC transgenic mice [19](#path5374-bib-0019){ref-type="ref"}, which carry two additional copies of the *Cisd2* gene (see supplementary material, Figure [S1](#path5374-supitem-0001){ref-type="supplementary-material"}A). We found that the level of Cisd2 protein was elevated by more than two‐fold in the hippocampus and cortex of our AD;Cisd2TG mice (AD mice carrying the *Cisd2* transgene) compared with littermates carrying either the AD only or WT genotype (see supplementary material, Figure [S1](#path5374-supitem-0001){ref-type="supplementary-material"}B). Our previous study revealed the mean lifespan of WT and Cisd2TG female mice to be 26.28 + 0.41 and 31.22 + 0.96 months, respectively [13](#path5374-bib-0013){ref-type="ref"}. By 12 months of age, both the Cisd2TG and WT female mice have a 100% survival rate (Figure [1](#path5374-fig-0001){ref-type="fig"}A). However, the AD female mice were found to have a significantly lower survival rate compared to WT controls. Intriguingly, Cisd2 overexpression significantly increased the survival rate of the AD;Cisd2TG female mice (Figure [1](#path5374-fig-0001){ref-type="fig"}A). Less than 40% of the AD female mice survived to 4 months of age; however, on the other hand, more than 80% of the AD;Cisd2TG female mice survived to 4 months of age. By way of contrast, there was no overt effect of Cisd2 on the survival rate of AD male mice; this is probably because the survival rate of males from this AD model is not significantly decreased compared to WT males (see supplementary material, Figure [S1](#path5374-supitem-0001){ref-type="supplementary-material"}C). Accordingly, from this point onward we focused mainly on the characterization of the female mice. Furthermore, our results showed that Cisd2 overexpression had no overt effect on the amyloid burden of these mice as revealed by western blotting (Figure [1](#path5374-fig-0001){ref-type="fig"}B) and on thioflavin‐S staining of the extracellular Aβ plaques present in the cortex and hippocampus when the surviving AD and AD;Cisd2TG mice are compared at 12 months of age (Figure [1](#path5374-fig-0001){ref-type="fig"}C,D).

![Overexpression of Cisd2 prevents premature death and reduces neuronal loss in female AD mice. (A) Premature lethality among female AD mice (APPswe and PS1‐dE9 double transgenic) can be recorded as early as 1 month of age, and \>60% of female AD mice died by 4 months. Two‐fold overexpression of Cisd2 in female AD mice was able to partially rescue this premature mortality and increased their survival rate. The animal numbers of each group ranged from 12 to 36 mice. (B) Western blotting analysis revealed that AD and AD;Cisd2TG mice both exhibited similar levels of precursor APP and soluble Aβ species in their hippocampus and cortex. Total protein extracts from the hippocampus and cortex of 9‐month‐old mice were separated using 15% Tricine‐SDS PAGE and detected using 6E10 antibody. (C) Thioflavin‐S staining detects extracellular Aβ plaques in WT, AD, Cisd2TG, and AD;Cisd2TG female mice. (D) Quantification of Aβ plaque number in cortex and hippocampus. Total areas of Aβ were measured using MetaMorph by setting a threshold for fluorescent intensity, and then dividing by the counting area within the hippocampus. Total areas of Aβ were divided by the number of Aβ areas in order to measure the average size of the Aβ. No significant difference in the Aβ plaque burden and average size between AD and AD;Cisd2TG mice were found. (E) Target region of interest (ROI) definitions. The ROI shows the area of hippocampus and was rendered onto the mouse brain using 2D and 3D views for the WT, AD, Cisd2TG, and AD;Cisd2TG brains. (F) Ratio of hippocampus versus whole brain volume, which was measured using TDI images. (G) DTI in the hippocampus of the WT, AD, Cisd2TG, and AD;Cisd2TG mice. (H) Quantification of mean diffusivity in the cornu ammonis 3 (CA3). (I) Nissl staining of neurons in the hippocampus (CA3) of the WT, AD, Cisd2TG, and AD;Cisd2TG mice. (J) Calculation of neuron numbers in CA3. For (C--J) mice were 12‐months‐old. Mean ± SD. \**p* \< 0.05, \*\**p* \< 0.005.](PATH-250-299-g001){#path5374-fig-0001}

Using MRI analysis, the results for track density imaging (TDI) showed that the ratio between hippocampus volume and total brain volume was significantly increased in AD female mice, whereas Cisd2 overexpression resulted in a slight decrease in this ratio (Figure [1](#path5374-fig-0001){ref-type="fig"}E,F). Nevertheless, we were not able to detect any significant differences in the brain and hippocampus volumes among the various different groups (see supplementary material, Figure [S1](#path5374-supitem-0001){ref-type="supplementary-material"}D,E). The diffusion parameters obtained from TDI revealed higher diffusivity in the CA3 region of hippocampus of the AD females, and, furthermore, Cisd2 overexpression appeared to reduce this diffusivity (Figure [1](#path5374-fig-0001){ref-type="fig"}G,H); however, such a phenotypic effect was not detected in the CA1 and dentate gyrus (DG) regions of the AD;Cisd2TG mice (see supplementary material, Figure [S1](#path5374-supitem-0001){ref-type="supplementary-material"}F,G). Higher diffusivity indicates that more neuronal cell loss has occurred in that brain region [20](#path5374-bib-0020){ref-type="ref"}. Indeed, our pathological analysis revealed there was a significant decrease in neuron numbers in the CA3 region of hippocampus of the AD mice; intriguingly, Cisd2 overexpression protected against this neuronal loss and rescued this defect (Figure [1](#path5374-fig-0001){ref-type="fig"}I,J; see supplementary material, Figure [S1](#path5374-supitem-0001){ref-type="supplementary-material"}H). Immunofluorescence (IF) staining for neuronal markers further validated the neuroprotective effect of Cisd2. Results for NeuN (neuron‐specific nuclear protein) (Figure [2](#path5374-fig-0002){ref-type="fig"}A,B) and MAP2 (a marker for neuronal cell body and dendrites) (see supplementary material, Figure [S1](#path5374-supitem-0001){ref-type="supplementary-material"}I,J) staining showed neuronal loss in the hippocampus of AD females, and remarkably, Cisd2 overexpression appeared to significantly reduce neuronal loss and helped to maintain neuronal integrity. To understand the potential cause(s) of the increased hippocampus/brain ratio in AD mice, we analyzed the numbers of microglia and astrocytes by IF staining for the microglial marker, ionized calcium‐binding adapter molecule 1 (Iba1), and the astrocytic marker, glial fibrillary acidic protein (GFAP), respectively. The results revealed that Iba1 signals were significantly elevated in AD mice, whereas Cisd2TG and WT control mice had similarly (low) levels of Iba1 signals (Figure [2](#path5374-fig-0002){ref-type="fig"}C,D; see supplementary material, Figure [S1](#path5374-supitem-0001){ref-type="supplementary-material"}K,L). This suggests that the increase in hippocampus/brain ratio is likely to be attributable, at least in part, to an increase in the number of glial cells present. Collectively, these results indicated that Cisd2 was able to protect the hippocampus from Aβ‐induced neuronal loss, to attenuate microglia expansion, and to reduce the level of inflammation in AD mice.

![Overexpression of Cisd2 alleviates neuronal loss and inflammation in female AD mice. (A) (B) IF staining for NeuN (red) reveals a reduced number of neurons in the granule cell layer (A) and hilus (B) of the dentate gyrus (DG) in the hippocampus of AD mice. (C) IF staining for Iba1, a microglia marker, in the hippocampus of the WT, AD, Cisd2TG, and AD;Cisd2TG mice. (D) Density quantification of Iba1+ cells obtained from three sections per mouse and three mice for each group. All mice were 12‐months‐old. Mean ± SD. \**p* \< 0.05, \*\**p* \< 0.005.](PATH-250-299-g002){#path5374-fig-0002}

Cisd2 deficiency accelerates Aβ‐mediated pathogenesis in the AD brain {#path5374-sec-0009}
---------------------------------------------------------------------

Cisd2 levels decrease in an age‐dependent manner in the brains of mammals during natural aging [16](#path5374-bib-0016){ref-type="ref"}. Because 'aging' is the major risk factor for AD, it is important to investigate whether Cisd2 deficiency accelerates AD pathogenesis and exacerbates the AD phenotype. To this end, we generated AD mice carrying a Cisd2KO background (AD;Cisd2KO) (see supplementary material, Figure [S2](#path5374-supitem-0001){ref-type="supplementary-material"}A). At 2 months of age, although amyloid deposition was not yet detectable in the AD brain (see supplementary material, Figure [S2](#path5374-supitem-0001){ref-type="supplementary-material"}B), the 2D and 3D views by TDI already revealed an enlarged brain volume in the AD mice; in particular, the hippocampus/brain ratio is significantly increased in the AD;Cisd2KO mice (Figure [3](#path5374-fig-0003){ref-type="fig"}A--[3](#path5374-fig-0003){ref-type="fig"}C). No obvious difference in hippocampus diffusivity was observed among various groups (see supplementary material, Figure [S2](#path5374-supitem-0001){ref-type="supplementary-material"}C--F). However, a pathological analysis revealed that neuron numbers in the CA3 region were significantly decreased in the Cisd2KO and AD;Cisd2KO mice (Figure [3](#path5374-fig-0003){ref-type="fig"}D,E), and that more severe neuronal damage was observed in the AD;Cisd2KO mice compared to the AD and Cisd2KO mice, as revealed by staining of neuronal markers Map2 and NeuN, respectively (Figure [3](#path5374-fig-0003){ref-type="fig"}E). Furthermore, the numbers of microglia (Iba1 positive) were significantly increased in the AD and Cisd2KO mice, and this was even more pronounced in the AD;Cisd2KO mice (Figure [3](#path5374-fig-0003){ref-type="fig"}G,H). The numbers of astrocytes (GFAP positive) also seems to have increased in AD, Cisd2KO, and AD;Cisd2KO mice compared to WT mice (see supplementary material, Figure [S2](#path5374-supitem-0001){ref-type="supplementary-material"}G,H). Together, these results reveal that Cisd2 deficiency not only damages neurons but also accelerate AD pathogenesis in mice.

![Cisd2 deficiency accelerates AD pathogenesis in mice. (A) Target region of interest (ROI) definitions. The ROI shows the area of hippocampus and was rendered on the mouse brain using 2D and 3D views. (B) Measurement of the volume of whole brain and hippocampus for the WT, AD, Cisd2KO, and AD;Cisd2KO female mice. The results were obtained from TDI images. (C) Volume ratio of hippocampus versus whole brain measured from TDI images. (D) Nissl staining of neurons in the CA3 of the hippocampus of WT, AD, Cisd2KO, AD;Cisd2KO female mice. (E) Quantification of neuron numbers in CA3. (F) Reduced immunoreactivity for MAP2 (green) in the CA1 and DG of the hippocampus was observed in the AD;Cisd2KO mice. Reduced immunoreactivity for NeuN (red) in the granule cell layer of DG of the hippocampus was also detected in the AD;Cisd2KO mice compared with the AD and Cisd2KO mice. (G) IF staining for Iba1, a microglia marker, in the hippocampus of the WT, AD, Cisd2KO, and AD;Cisd2KO mice. (H) Density quantification of Iba1+ cells. The results were obtained from three brain sections per mouse and three mice for each group. Mice were 2‐months‐old. Mean ± SD. \**p* \< 0.05.](PATH-250-299-g003){#path5374-fig-0003}

Cisd2 protects mitochondria and attenuates the loss of neuronal progenitor cells {#path5374-sec-0010}
--------------------------------------------------------------------------------

To understand how Cisd2 overexpression ameliorates AD pathogenesis, we analyzed the neuronal progenitor cell population in the hippocampus. Notably, there were fewer proliferative cells (Ki‐67+ cells) and fewer neuronal progenitor cells (Dcx + or Tbr2+ cells) in the subgranular zone of the AD hippocampus, and Cisd2 overexpression seems to partially rescue this defect as well as significantly increase the number of neuronal progenitor cells present (Figure [4](#path5374-fig-0004){ref-type="fig"}A,B). Ultrastructural examination of the hippocampus showed that the total number of synapses has no obvious difference among different groups, but Cisd2 did increase the relative ratio of excitatory versus inhibitory synapses in the AD;Cisd2TG mice (Figure [4](#path5374-fig-0004){ref-type="fig"}C; see supplementary material, Figure [S3](#path5374-supitem-0001){ref-type="supplementary-material"}A--E). The increase of the excitatory synapses suggests that there may be more neurons present that can generate new action potentials and transmit the information to another cell, thus helping to restore neuronal functionality [21](#path5374-bib-0021){ref-type="ref"}. In addition, we monitored mitochondrial function and found that the OCR is significantly decreased in the AD mice, indicating a functional decline of mitochondria in terms of oxidative phosphorylation and the generation of ATP. Remarkably, Cisd2 overexpression rescues this mitochondrial defect in energy production (Figure [4](#path5374-fig-0004){ref-type="fig"}D). In the hippocampus of AD mice, mitochondrial breakdown accompanied by autophagosome and autolysosome activity is a distinctive pathological feature; strikingly, in the AD;Cisd2TG mice, Cisd2 overexpression seems to revert these morphological abnormalities and move these mice toward a more normal state (Figure [4](#path5374-fig-0004){ref-type="fig"}E). These results reveal that Cisd2 overexpression in AD mice can protect mitochondria from the Aβ‐induced structural defects and functional damage that affect ATP production, as well as attenuate the progressive loss of the neuronal progenitor cells.

![Elevated expression of Cisd2 attenuates the loss of neuronal progenitor cells and protects against Aβ‐induced mitochondrial defects. (A) Immunohistochemical staining of brain sections to label Doublecortin (Dcx), T‐box brain protein 2 (Tbr2), and antigen Ki‐67 (Ki67) in order to detect neuronal progenitor cells. (B) Quantification of cells positive for Dcx, Tbr2, and Ki‐67 in the DG region. (C) Excitatory (asymmetric) and inhibitory (symmetric) synapses revealed by TEM. Arrow indicates asymmetric synapses and arrowhead indicates symmetric synapses. Quantification results for the ratio of excitatory synapses to inhibitory synapses. (D) OCR measured using Seahorse equipment and hippocampus tissue samples obtained from the various groups of mice. (E) Ultrastructure of mitochondria in the hippocampus of the WT, AD, and AD;Cisd2 TG female mice. The mice used to create this figure were 12‐months‐old. Mean ± SD. \**p* \< 0.05; \*\**p* \< 0.005.](PATH-250-299-g004){#path5374-fig-0004}

Cisd2 shifts the expression patterns of dysregulated genes in AD toward WT mice {#path5374-sec-0011}
-------------------------------------------------------------------------------

To understand the molecular mechanism underlying the neuroprotective effect of Cisd2 in AD, we performed RNA sequencing using total RNA obtained from the hippocampus of WT, AD, and AD;Cisd2TG mice. Three sets of pair‐wise differential expression analysis were performed: these were between WT and AD mice (Set‐1), between AD;Cisd2TG and AD mice (Set‐2), and between WT and AD;Cisd2TG mice (Set‐3). A false discovery rate (FDR) less than 0.05 was set as significance threshold value. From these three sets of differentially expressed genes (DEGs), we select genes that were differentially expressed in Set‐1, that is, they showed a significant change in expression due to the AD genotype and that, in Set‐2, showed a significant change in expression due to Cisd2 overexpression, but were not differentially expressed in Set‐3. Thus their expression levels were not significantly different from their values in WT. A total of 154 genes were identified using these selection criteria (see supplementary material, Table [S1](#path5374-supitem-0002){ref-type="supplementary-material"}). These findings indicate that Cisd2 overexpression may be able to reverse the expression pattern of a panel of dysregulated genes in the hippocampi of AD mice and move the expression pattern back toward one that is similar to that of WT mice (Figure [5](#path5374-fig-0005){ref-type="fig"}; a high resolution figure with gene symbols is provided in supplementary material, Figure [S4](#path5374-supitem-0001){ref-type="supplementary-material"}).

![Cisd2 reverses the expression pattern of a panel of differentially expressed genes in the hippocampus of AD mice. The genes that showed significant difference in expression between the 'WT and AD', mice and between the AD;Cisd2TG and AD" mice, as well as having the same trend of expression changes were selected (FDR \<0.05). A total of 154 genes were selected that showed high dissimilarity according to these criteria. The heat map reveals that Cisd2 overexpression in the AD;Cisd2TG mice shifts the expression patterns of the 154 genes toward the WT mice. Consensus clustering was performed, and this resulted in eight gene clusters. The intensities of gene expression are depicted in colors that range from blue (log2 count‐per‐million −1 and lower) to red (log2 count‐per‐million 1 and higher). A more detailed version of this figure listing the genes forming the clusters is provided as supplementary material, Figure [S4](#path5374-supitem-0001){ref-type="supplementary-material"}.](PATH-250-299-g005){#path5374-fig-0005}

The 154 DEGs can be classified into various different functional categories, namely, synapse‐related functions, mitochondrial functions, ion homeostasis, protein or organelle degradation and cell death, cellular and extracellular structure maintenance, cell cycle, transcriptional regulators, enzymes (except those found in mitochondria), and various others (see supplementary material, Table [S1](#path5374-supitem-0002){ref-type="supplementary-material"}). In addition, when we compared our transcriptomic data with the GeneCards database, the expression levels of four AD‐associated genes --namely, aquaporin 1 (*Aqp1*), alpha‐2 macroglobulin (*A2m*), angiotensin‐converting enzyme (*Ace*), and transthyretin (*Ttr*) -- were dramatically increased by Cisd2 overexpression in the AD;Cisd2TG mice. However, these four genes are not downregulated in AD mice (see supplementary material, Figure [S5](#path5374-supitem-0001){ref-type="supplementary-material"}). Of interest, several of the selected DEGs are known to be associated with mitochondrial metabolism and synaptic neurotransmission (Figure [6](#path5374-fig-0006){ref-type="fig"}). For example, Ras‐related protein Rab‐3C (*Rab3c*) and syntaxin 1B (*Stx1b*) are necessary for the regulation of synaptic vesicle transport and exocytosis [22](#path5374-bib-0022){ref-type="ref"}, [23](#path5374-bib-0023){ref-type="ref"}. Calcium voltage‐gated channel auxiliary subunit alpha2delta 1 (*Cacna2d1*), a voltage‐dependent calcium channel, is critical to excitation‐contraction coupling on both presynaptic and postsynaptic neuronal membranes [24](#path5374-bib-0024){ref-type="ref"}. Glutamate decarboxylase 65 (Gad65), encoded by *Gad2*, undergoes activity‐dependent expression in axon terminals and is responsible for the synthesis and vesicle release of γ‐aminobutyric acid (GABA), an inhibitory neurotransmitter [25](#path5374-bib-0025){ref-type="ref"}. Finally, glutamate receptor 1 (*Gria1*) is the prevailing excitatory neurotransmitter receptor and is involved mainly in synaptic plasticity [26](#path5374-bib-0026){ref-type="ref"}. The GABA receptor (*Gabra*) is located post‐synapse and interacts with GABA to deliver the inhibitory signals [27](#path5374-bib-0027){ref-type="ref"}. Thus, in summary, our transcriptomic analysis has revealed that Cisd2 overexpression seems to be able to reverse and rescue the expression patterns of a panel of genes dysregulated by AD, including genes that are crucial to the functioning of both mitochondria and synapses.

![An overview of the possible effects of the genes dysregulated during AD that are can be reversed by Cisd2 overexpression and are involved in mitochondrial respiration and signal transduction during synaptic neurotransmission. Synapses demand a high energy supply from the mitochondria together with well‐controlled calcium homeostasis in order to permit the correct signal transduction from one neuron to another. In the hippocampus of AD mice, transcriptomic analysis revealed dysregulation of complex (Cx) genes (upregulation of Cx I and III and downregulation of Cx II and IV), which are essential components of electron transport chain that produces ATP. In addition, genes involved in the synapse neurotransmission are over‐activated (marked in red at the synapses); this might be a compensatory effect in response to neurodegeneration. It is notable that Cisd2 overexpression can reverse the abnormal expression pattern of these dysregulated genes and return them to a level similar to that found in WT mice.](PATH-250-299-g006){#path5374-fig-0006}

Discussion {#path5374-sec-0012}
==========

Implication of the findings {#path5374-sec-0013}
---------------------------

There are several new findings in this study. First, using this APP/PS1 mouse model, the dosage of Cisd2 present in the mice modulates the severity of the AD phenotypes. Second, Cisd2 protects against mitochondrial damage, protects against mitochondrial functional decline, and attenuates the loss of neurons and neuronal progenitor cells that occurs in the hippocampus of AD mice. Finally, an increase in Cisd2 reverses the abnormal expression pattern of a panel of genes that are dysregulated in AD; these are returned to an expression pattern similar to that of WT mice. The genes modulated by increased Cisd2 expression include ones that are involved in mitochondrial functioning within the presynaptic terminal of axons, in the release of neurotransmitters from synaptic vehicles, and in the passing of signals via receptor binding during neurotransmission. The above‐mentioned findings suggest that with higher Cisd2 expression there is a recovery of neuronal function and an attenuation of neuronal loss. These changes will ultimately ameliorate Aβ‐induced pathogenesis in the hippocampus of the AD mice. Alternatively, it is also possible that this shift in gene expression might be a secondary consequence of the neuroprotective effects of Cisd2, whereby it protects mitochondria from damage and thus maintains synaptic function.

Cisd2 upregulation attenuates AD progression {#path5374-sec-0014}
--------------------------------------------

### Neuroinflammation and the size of the hippocampus in the AD brain {#path5374-sec-0015}

Previous reports have shown that brain size, especially the size of hippocampus, decreased gradually as the disease progresses in AD patients and that this is also true for certain AD mouse models [28](#path5374-bib-0028){ref-type="ref"}. However, in some of AD mouse models, the volume of the hippocampus and whole brain show no obvious differences [29](#path5374-bib-0029){ref-type="ref"}, [30](#path5374-bib-0030){ref-type="ref"}. Of interest, our TDI images showed that the ratio of the hippocampus versus whole brain was significantly increased in 12‐month‐old female AD mice. However, enhanced Cisd2 expression seemed to be able to rescue this phenotype and reduce the hippocampal volume to a size like that of the WT controls. Neuronal loss accompanied by neuroinflammation is a pathological hallmark of AD in human patients and mouse models. When amyloid oligomers begin to form in cells and extracellular spaces of the brain, the misfolded and aggregated proteins are recognized by microglia and astrocytes; this then triggers further immune responses, resulting in a vicious cycle [31](#path5374-bib-0031){ref-type="ref"}, [32](#path5374-bib-0032){ref-type="ref"}. Activated microglia are able to clean up debris and misfolded proteins; however, activated microglia are also harmful to neurons and participate in amyloid‐dependent synapse loss [33](#path5374-bib-0033){ref-type="ref"}. In the present study, our results revealed that the hippocampus is enlarged in the AD mice and that this is accompanied by neuronal loss and severe neuroinflammation, as well as proliferation of microglia. One possible explanation for the enlarged hippocampus may be the increased number of microglia accumulating in the hippocampus of AD mice. Intriguingly, Cisd2 overexpression seems to attenuate neuronal loss and decrease the number of activated microglia, thereby reducing the size of the hippocampus.

### Synaptic neurotransmission and mitochondrial function {#path5374-sec-0016}

Among human patients with neurodegenerative diseases, synapse loss is a critical feature during the early stages of the disease process [34](#path5374-bib-0034){ref-type="ref"}. Substantial evidence indicates that, in AD, there is a decrease in the number of synapses, and that this occurs later than Aβ accumulation and is correlated with disease progression [35](#path5374-bib-0035){ref-type="ref"}, [36](#path5374-bib-0036){ref-type="ref"}. Dysregulation of several presynaptic and postsynaptic pathways may contribute to AD pathogenesis. Most interestingly, microglia play a direct role in neurodegeneration, especially of the synapse; this seems to occur via a modulation of the phagocytotic process [37](#path5374-bib-0037){ref-type="ref"}. In our study, Cisd2 overexpression reversed the expression of several crucial genes that are known to be involved in synaptic neurotransmission (Figure [6](#path5374-fig-0006){ref-type="fig"}); consequently, these changes may further improve the functioning of the synapse in the hippocampus of AD mice. In addition, previous studies have shown that an altered mitochondrial structure can lead to cerebral hypometabolism in AD‐affected brain regions [38](#path5374-bib-0038){ref-type="ref"}, [39](#path5374-bib-0039){ref-type="ref"}. Morphometric analysis in such circumstances has revealed that AD brain has significantly fewer mitochondria, and this is accompanied by increased ROS accumulation [38](#path5374-bib-0038){ref-type="ref"}. Mitochondrial enzyme abnormalities underlie most of enzyme deficits affecting the AD brain, for example, cytochrome oxidase, the α‐ketoglutarate dehydrogenase complex, and the pyruvate dehydrogenase complex [40](#path5374-bib-0040){ref-type="ref"}, [41](#path5374-bib-0041){ref-type="ref"}. Numerous studies have demonstrated that increased Aβ accumulation contributes to structural and functional mitochondrial abnormalities, including effects on membrane potential, fusion/fission, transport, ROS production, and electron transfer chain [42](#path5374-bib-0042){ref-type="ref"}. Intriguingly, elevated levels of Cisd2 protein appear to protect against mitochondrial breakdown, as revealed by ultrastructural examination using transmission electron microscopy (TEM), and attenuate Aβ‐mediated toxicity that affects mitochondrial function, as revealed by measuring the OCR of the electron transport chain.

Cisd2 overexpression leads to upregulation of four genes that have beneficial effects in relation to AD {#path5374-sec-0017}
-------------------------------------------------------------------------------------------------------

Expression levels of the four genes, namely, *Aqp1*, *A2m*, *Ace* and *Ttr*, were found to be significantly increased in the hippocampus of AD mice when there was Cisd2 overexpression, although expression of these genes showed no significant difference when the AD and WT mice were compared. *Aqp1* encodes an astrocytic water channel that can facilitate the maintenance of water homeostasis. Because Aβ accumulation interferes with the functioning of aquaporin 1, causing abnormalities in water homeostasis [43](#path5374-bib-0043){ref-type="ref"}, an increased Aqp1 expression may have a beneficial effect on astrocytes at the site of Aβ depositions, which in turn may help them to degrade Aβ [44](#path5374-bib-0044){ref-type="ref"}. Acute‐phase protein A2m, which functions as a pan‐protease inhibitor, is an important component of the innate immune system. In addition, A2m is able to bind to misfolded aggregation‐prone proteins [45](#path5374-bib-0045){ref-type="ref"}. ACE had been reported to be able to facilitate the degradation of Aβ, to be able to enhance immune responses and to help to prevent cognitive decline in AD models [46](#path5374-bib-0046){ref-type="ref"}. Finally, Ttr, which is an Aβ‐binding protein, has been reported to have proteolytic activity and can act as a neuroprotector in AD models [47](#path5374-bib-0047){ref-type="ref"}. The elevated expression of these four genes in the AD;Cisd2TG mice is likely to help to protect against Aβ‐mediated damage and thus attenuate disease severity.

Diffusivity imaging may facilitate the monitoring of AD pathogenesis within the brain {#path5374-sec-0018}
-------------------------------------------------------------------------------------

TDI imaging allows high level resolution images to be captured and provides high anatomical contrast using a new MRI contrast mechanism. Previously, Calamante *et al*. have demonstrated that the TDI technique can provide meaningful and rich anatomical contrast results at a level similar to the information obtained using histological staining in the same brains [48](#path5374-bib-0048){ref-type="ref"}. TDI combined with diffusion tensor imaging (DTI) has been used to characterize microstructural changes and differences in neuropathology [49](#path5374-bib-0049){ref-type="ref"}. In this study, we substituted traditional structural imaging with TDI; our results revealed that TDI can indeed provide an improved spatial resolution and enhanced contrast between the grey matter and white matter. In addition, TDI can contour the hippocampal volume more precisely, and the diffusivity index of the TDI seems to represent the microstructure of neuronal tissue in the brain. Therefore, TDI should be able to offer, in the future, a noninvasive means for monitoring pathogenic progression in human patients with AD.

Finally, we have, by integrating different technology platforms across multiple disciplines, including brain imaging, mouse genetics, molecular pathology, and transcriptomics analysis, provided important evidence showing that Cisd2 overexpression is an effective way of attenuating Aβ‐mediated neuronal cell death and neuro‐inflammation; thus Cisd2 overexpression would seem to slow the progression of AD. Finally, we have provided evidence in this study to indicate that Cisd2‐based therapies hold great promise to serve as disease‐modifying strategies for AD.
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